Docetaxel-fatty acid prodrug compound as well as preparation and application thereof
By designing docetaxel-fatty acid prodrug compounds and their self-assembled nanoparticles, using chemical link chains and configuration modifications of different lengths, the problems of low absorption efficiency and great side effects of docetaxel are solved, and the tumor is achieved The release of specific drugs in cells and the improvement of therapeutic efficacy provide a new strategy for efficient and low-toxic chemotherapy.
Patent Information
- Application Number
- CN202310631352.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-05-31
AI Technical Summary
The oral absorption efficiency of docetaxel is low, resulting in poor oral bioavailability, and the existing injection dosage forms have side effects and insufficient anti-tumor activity.
A docetaxel-fatty acid prodrug compound and its self-assembled nanoparticles were designed to form nanoparticles with small particle size and uniform particle size distribution through chemical link chains and configurations of different lengths for drug delivery. Improve efficacy and reduce toxicity in the system.
It effectively improves the efficacy of docetaxel, reduces its toxic side effects, and achieves the release and attenuation of specific drugs in tumor cells, providing a new strategy for the development of highly effective and low-toxic chemotherapy preparations.
Smart Images

Figure BDA0004258474290000021 
Figure BDA0004258474290000022 
Figure BDA0004258474290000023
Abstract
Description
Technical field:
[0001] The invention belongs to the field of new excipients and new dosage forms of pharmaceutical preparations, and specifically relates to the construction of a docetaxel-fatty acid prodrug compound and self-assembled nanoparticles thereof, and application of the compound in a drug delivery system. Background technology:
[0002] In recent years, the incidence of malignant tumors has been increasing, seriously threatening human health. Chemotherapy is one of the most effective strategies for cancer treatment. Docetaxel (DTX) belongs to the taxane class of anti-tumor drugs, which has strong cytotoxicity and anti-tumor effects. However, the oral absorption efficiency of DTX is extremely low, resulting in poor oral bioavailability. DTX is formulated into an injection form (Taxotere: ) has become the only choice for its clinical application. However, a large amount of Tween 80 and ethanol are used to dissolve DTX in commercially available injections, resulting in serious side effects related to excipients. More importantly, Taxotere is rapidly metabolized after intravenous administration, with less tumor accumulation and poor antitumor activity. Therefore, designing and implementing an efficient and safe drug delivery system has always been required for clinical chemotherapy.
[0003] Nano drug delivery systems can effectively prolong the circulation time of drugs in the body and enhance the anti-tumor effect. Prodrug strategy is an effective method to improve the efficiency of chemotherapy drug delivery. Structural modification of docetaxel through prodrug strategy can effectively improve the problems of poor solubility and large toxic side effects of docetaxel. Therefore, the self-assembled nano drug delivery system based on prodrug strategy combines the advantages of nanotechnology and prodrug strategy, and has the advantages of high drug loading and no need for solubilizers, and has been widely studied in recent years.
[0004] Prodrug assemblies are usually composed of three parts: the parent drug, the connecting chain and the side chain. The connecting chain connects the parent drug and the side chain together. Aliphatic side chains can increase the structural flexibility of prodrug molecules, balance the intermolecular forces, and promote the self-assembly of prodrugs. Studies have found that different chemical connecting bonds can also affect the redox sensitivity of prodrug self-assembled nanoparticles, thereby affecting the anti-tumor activity of prodrug self-assembled nanoparticles. With the change of the chemical connecting chain, the safety and effectiveness of the drug will be affected.
[0005] The tumor microenvironment is significantly different from the microenvironment of normal tissue cells. A large amount of reactive oxygen and glutathione are produced in tumor cells, resulting in an unbalanced tumor microenvironment with redox state. The effectiveness and safety of prodrug nanocombinations are often a relationship that cannot be achieved at the same time. Once the linker is too active, the prodrug will release active drugs in the systemic circulation, thereby causing toxicity. If the linker is too stable, it will be difficult for tumor cells to release active drugs, affecting the anti-tumor effect. Therefore, reasonable regulation of the sensitivity of the linker is the key to designing a combination of efficient and low-toxic drugs. Chinese patent CN2020106659037 records that taxane-fatty acid prodrugs with 2,2'-dithiodiacetic acid as the linker have excellent anti-tumor effects, but their safety is slightly poor. Therefore, prodrugs that can take into account both effectiveness and safety are the focus of current research. Summary of the invention:
[0006] The purpose of the present invention is to design a docetaxel-fatty acid prodrug compound and the construction of its self-assembled nanoparticles, as well as the application of the compound in a drug delivery system.
[0007] To achieve the above object, the present invention adopts the following technical solutions:
[0008] A docetaxel-fatty acid prodrug compound, the compound being a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof,
[0009]
[0010] Wherein, n=2 or 3; R is oleic acid.
[0011] The compound is the following compound or a pharmaceutically acceptable salt thereof,
[0012] When n=2 in the general formula (I), it is docetaxel-oleic acid prodrug (β-DTX-SS-OA) with 3,3'-dithiodipropionic acid as the connecting chain;
[0013]
[0014] When n=3 in the general formula (I), it is docetaxel-oleic acid prodrug (γ-DTX-SS-OA) with 4,4'-dithiodibutyric acid as the connecting chain.
[0015]
[0016] A method for synthesizing the docetaxel-fatty acid prodrug compound:
[0017] Step 1: The fatty acid reacts with ethylene glycol under the catalysis of p-toluenesulfonic acid to obtain fatty acid-ethylene glycol ester;
[0018] Step 2: The fatty acid-ethylene glycol ester undergoes a ring-opening esterification reaction with a dibasic acid anhydride (3,3'-dithiodipropionic anhydride or 4,4'-dithiodibutyric anhydride) under the catalysis of DMAP to obtain an intermediate product;
[0019] Step 3: The intermediate product undergoes an esterification reaction with docetaxel under the catalysis of HOBt, EDCI and DMAP, and is separated and purified to obtain the compound represented by the general formula (I).
[0020] In the step 1, the molar ratio of p-toluenesulfonic acid: fatty acid: ethylene glycol is 1:(1-3):(5-15).
[0021] In the step 2, the molar ratio of DMAP: fatty acid-ethylene glycol ester: dibasic acid anhydride is 1:(1-10):(5-15).
[0022] In the step 3, the molar ratio of intermediate product:HOBt:EDCI:DMAP:docetaxel=1:(1-10):(2-6):(0.2-5):(0.5-10).
[0023] Further, it is said that
[0024] Step 1: Using p-toluenesulfonic acid as a catalyst, slowly drip the fatty acid into the ethylene glycol solution, stir at 110° C. for 2-3 hours, and separate by column chromatography to obtain fatty acid-ethylene glycol ester; wherein the fatty acid is oleic acid;
[0025] Step 2: dissolving a dibasic acid in acetic anhydride and stirring for 2-4 hours to convert the dibasic acid into anhydride, adding toluene after the reaction is completed, and removing toluene and acetic anhydride by rotary evaporation to obtain a dibasic acid anhydride; wherein the dibasic acid is 2,2'-dithiodiacetic acid, 3,3'-dithiodipropionic acid or 4,4'-dithiodibutyric acid;
[0026] The fatty acid-ethylene glycol ester, dibasic acid anhydride and 4-dimethylaminopyridine (DMAP) obtained above are dissolved in dichloromethane, stirred at room temperature for 12-18 hours, and separated by column chromatography to obtain an intermediate product;
[0027] Step 3: Take 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1-hydroxybenzotriazole (HOBt) and 4-dimethylaminopyridine (DMAP), and dissolve them together with the intermediate product in anhydrous dichloromethane. After stirring in an ice bath for 2-4 hours, docetaxel is added, and stirred at room temperature for 24-48 hours. Then, the final product is separated and purified by preparative liquid phase separation. The above reaction is carried out under nitrogen protection throughout the process.
[0028] A docetaxel-fatty acid prodrug compound self-assembled nanoparticle:
[0029] The prodrug compound self-assembled nanoparticles represented by the general formula (I) are non-PEGylated small molecule prodrug self-assembled nanoparticles, PEG-modified / active targeting group-modified small molecule prodrug self-assembled nanoparticles, or small molecule prodrug self-assembled nanoparticles encapsulating fluorescent substances / hydrophobic drugs.
[0030] The non-PEGylated small molecule prodrug self-assembled nanoparticles are:
[0031] (1) dissolving the prodrug compound represented by the general formula (I), and adding the dissolved solution dropwise into water under stirring conditions, so that docetaxel-fatty acid prodrug spontaneously forms uniform nanoparticles;
[0032] (2) removing the organic solvent in the preparation by a reduced pressure rotary evaporation method to obtain non-PEGylated small molecule prodrug self-assembled nanoparticles;
[0033] The PEG-modified / active targeting group-modified small molecule prodrug self-assembled nanoparticles:
[0034] (1) mixing and dissolving a modifier and a prodrug compound represented by the general formula (I), slowly dropping the solution into water under stirring conditions, and the docetaxel-fatty acid small molecule prodrug spontaneously forms uniform nanoparticles, wherein the modifier is a PEG modifier or an active targeting modifier, and the mass ratio is docetaxel-fatty acid small molecule prodrug: modifier=(20-1):1;
[0035] (2) removing the organic solvent in the preparation by a reduced pressure rotary evaporation method to obtain PEG-modified / active targeting group-modified small molecule prodrug self-assembled nanoparticles;
[0036] The small molecule prodrug self-assembled nanoparticles encapsulating the hydrophobic fluorescent substance or drug:
[0037] (1) Mixing and dissolving a PEG modifier, a hydrophobic fluorescent substance or a drug with a prodrug compound represented by the general formula (I), slowly dropping the solution into water under stirring conditions, and docetaxel-fatty acid small molecule prodrug spontaneously forms uniform nanoparticles; in terms of mass ratio, the prodrug compound represented by the general formula (I): PEG modifier: hydrophobic fluorescent substance or drug = (20-1): 1: (1-5);
[0038] (2) The organic solvent in the preparation is removed by a reduced pressure rotary evaporation method to obtain small molecule prodrug self-assembled nanoparticles encapsulating a hydrophobic fluorescent substance or a drug.
[0039] In the above preparation process, the organic solvent used for dissolving in each step (1) is ethanol, tetrahydrofuran or acetone;
[0040] The PEG modifier is an amphiphilic polymer or targeting group such as DSPE-PEG, TPGS, PLGA-PEG, PE-PEG or DSPE-PEG-FA, and the active targeting modifier is a sugar residue, hormone, receptor or ligand, such as an antibody, glycoprotein, lipoprotein, transferrin, polypeptide and folic acid.
[0041] An application of the docetaxel-fatty acid prodrug compound, the compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, or the docetaxel-fatty acid prodrug compound self-assembled nanoparticles in the preparation of an anti-tumor drug having both effectiveness and safety.
[0042] The docetaxel-fatty acid small molecule prodrug or self-assembled nanoparticles are used in preparing injection, oral or local administration systems.
[0043] The docetaxel-fatty acid small molecule prodrug or self-assembled nanoparticles are used in preparing a drug delivery system with improved efficacy and reduced toxicity.
[0044] Beneficial effects of the present invention:
[0045] (1) The present invention designs and synthesizes docetaxel-fatty acid small molecule prodrugs containing different lengths of connecting chains and different configuration modifications, and prepares docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles with small particle size and uniform particle size distribution. The synthesis method and preparation method are simple and easy to implement;
[0046] (2) The present invention designs and synthesizes docetaxel-fatty acid small molecule prodrugs containing different lengths of connecting chains and different configuration modifications and docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles, which can effectively improve the efficacy of docetaxel and reduce its toxic side effects; with the growth of the intermediate chemical connecting chain and the specific configuration, the docetaxel-fatty acid prodrug can not only specifically release the parent drug in the highly reducing environment in tumor cells, but also achieve the effect of reducing toxicity. The present invention provides a new strategy and option for the development of high-efficiency and low-toxic chemotherapy preparations. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 The structure of docetaxel-oleic acid prodrug (α-DTX-SS-OA) with 2,2'-dithiodiacetic acid as the connecting chain in the comparative example of the present invention is confirmed; A: 1 H-NMR spectrum, B: mass spectrum of α-DTX-SS-OA.
[0048] Figure 2The structural confirmation of docetaxel-oleic acid prodrug (β-DTX-SS-OA) with 3,3'-dithiodipropionic acid as the connecting chain in Example 1 of the present invention; A: 1 H-NMR spectrum, B: mass spectrum of β-DTX-SS-OA.
[0049] Figure 3 The structural confirmation of docetaxel-oleic acid prodrug (γ-DTX-SS-OA) with 4,4'-dithiodibutyric acid as the connecting chain in Example 2 of the present invention; A: 1 H-NMR spectrum, B: mass spectrum of γ-DTX-SS-OA.
[0050] Figure 4 : The particle sizes of docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles prepared in the examples and comparative examples of the present invention; A: particle size distribution diagram of α-DTX-SS-OA prodrug self-assembled nanoparticles, B: particle size distribution diagram of β-DTX-SS-OA prodrug self-assembled nanoparticles, C: particle size distribution diagram of γ-DTX-SS-OA prodrug self-assembled nanoparticles.
[0051] Figure 5 This is the FBS stability diagram of docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles in the examples of the present invention.
[0052] Figure 6 This is a graph showing the in vitro plasma chemical stability of docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles in an embodiment of the present invention.
[0053] Figure 7 Figures 1 and 2 are in vivo anti-tumor experimental diagrams of docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles in the embodiments of the present invention; A: Effect of docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles on the growth of subcutaneous breast cancer tumors in Balb / C mice, B: Effect of docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles on the body weight of tumor-bearing mice, C: Effect of docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles on the tumor-bearing rate of Balb / C mice, D: Tumor photos of Balb / C tumor-bearing mice after treatment with docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles.
[0054] Figure 8 This is an experimental diagram of the in vivo pharmacokinetics of docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles in an embodiment of the present invention. Specific implementation method:
[0055] The present invention is further described below by way of examples, but the invention is not limited to the scope of the examples.
[0056] The present invention synthesizes docetaxel-fatty acid small molecule prodrugs with chemical connection bonds at different positions, prepares the prodrug self-assembled nano drug delivery system, and uses the prodrug in drug delivery. The stability, cytotoxicity and pharmacodynamics of the obtained prodrug self-assembled nanoparticles provide new strategies and more options for developing tumor microenvironment intelligent responsive drug delivery systems, meeting the urgent demand for highly efficient chemotherapy preparations in clinical practice.
[0057] Example 1: Synthesis of docetaxel-oleic acid prodrug (β-DTX-SS-OA) with 3,3′-dithiodipropionic acid as the linker.
[0058] An appropriate amount of ethylene glycol (0.1 mmol) was placed in a three-necked flask, and p-toluenesulfonic acid (0.3 mmol) was added to the three-necked flask. The flask was heated to 110°C under N2 protection, and 5 mL of oleic acid (1 mmol) solution dissolved in toluene was slowly dripped into the reaction flask for 2-3 hours. The reaction was monitored to be complete by TLC. After the reaction was completed, the stratification was allowed to stand, and toluene was used to extract until the ethylene glycol layer showed no product on TLC. The toluene layers were combined and then washed with saturated NaHCO3 solution until neutral, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to obtain a reddish-brown oily liquid. The intermediate 1 was separated and purified by column chromatography using a cyclohexane-ethyl acetate elution system to obtain a colorless oily liquid.
[0059] A proper amount of 3,3'-dithiodipropionic acid (2mmol) was dissolved in 4mL acetic anhydride and placed in a 25mL eggplant-shaped bottle. After complete dissolution, the mixture was magnetically stirred at 25°C for 2 hours and then transferred to a 100mL eggplant-shaped bottle. Three times the amount of toluene was added. Toluene and acetic anhydride were removed by vacuum distillation. A proper amount of dichloromethane was added to dissolve the dithiodiacetic anhydride formed. Then, the intermediate 1 (1mmol) dissolved in dichloromethane was added. A solution of 4-dimethylaminopyridine (DMAP, 0.2mmol) dissolved in dichloromethane was slowly added dropwise. The mixture was magnetically stirred at 25°C for 12 hours. The intermediate product 2 is obtained, and the column chromatography is separated and purified using a cyclohexane-acetone elution system; after obtaining the purified product of the previous step (1mmol), a dichloromethane solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 2mmol), 1-hydroxybenzotriazole (HOBt, 1mmol), and 4-dimethylaminopyridine (DMAP, 0.5mmol) is added, activated in an ice bath at 0°C for 2 hours, and then docetaxel (0.8mmol) dissolved in dichloromethane is added, and stirred at 25°C for 36-48 hours. After the reaction is completed, the product is separated using a preparative phase to obtain a docetaxel-oleic acid prodrug (β-DTX-SS-OA) with 3,3'-dithiodipropionic acid as a connecting chain.
[0060] Mass spectrometry and nuclear magnetic resonance spectroscopy were used to determine the structure of the prodrug in Example 2. The results are as follows: Figure 2The results of nuclear magnetic resonance spectrum analysis are as follows: β-DTX-SS-OA.
[0061] 1 H NMR(600MHz,Chloroform-d)δ8.11(d,J=7.5Hz,2H,Ar-H),7.61(t,J=7.4Hz,1H,Ar-H),7.50(t,J=7.8Hz,2H,Ar-H),7.39(t,J=7.7Hz,2H,Ar-H),7. 34–7.27(m,3H,Ar-H),6.23(s,1H,-OCO-NH-),5.69(d,J=7.1Hz,1H,2'-H) ,5.53-5.43(m,2H,3'-H,-OH),5.38(s,1H,-OH),5.37–5.31(m,2H,-CH2-C H =C H -CH2-),5.23(s,1H,10- H ),4.96(dd,J=9.7,2.5Hz,1H,13-H),4.35–4.23(m,6H,20-C H 2a,2-H and-OC H2 C H2 O-), 4.19(d, J=8.6Hz,1H,20-C H 2b),3.93(d,J=7.2Hz,1H,5-H),2.89(t,J=7.1Hz,2H,-SC H2 ),2.86–2.80(m,4H,-SC H2 C H2 -),2.79-2.70(m,3H,-SCH2C H2 -,-OH),2.62–2.55(m,1H,7-H),2.43(s,3H,-OCOC H3 ),2.36-2.27(m,3H,-COC H2 CH2-,14-Ha),2.19-2.11(m,1H,14-Hb),2.03–1.99(m,4H,-C H2 -CH=CH-C H2 -),1.95(s,3H,18-C H3 ),1.90–1.81(m,2H,3-H,6-Ha),1.75(s,3H,19-C H3 ),1.68–1.59(m,3H,6-Hb,-OCOCH2C H2- ),1.39–1.24(m,29H,-C(CH3)3,-(CH2)10 ),1.23(s,3H,16-C H3 ),1.12(s,3H,17-C H3 ),0.88(t,J=7.0Hz,3H,-CH2C H3 ).
[0062] Mass spectrometry results are MS (ESI) m / z for C 69 H 97 NO 19 S2[M+Na] + =1330.6096.
[0063] Example 2: Synthesis of docetaxel-oleic acid prodrug (γ-DTX-SS-OA) with 4,4′-dithiodibutyric acid as the linker.
[0064] Synthesis of docetaxel-oleic acid prodrug (γ-DTX-SS-OA) with 4,4'-dithiodibutyric acid as a connecting chain The preparation method of Example 1 was adopted to replace 3,3'-dithiodipropionic acid with 4,4'-dithiodibutyric acid to obtain docetaxel-oleic acid prodrug (γ-DTX-SS-OA) with 4,4'-dithiodibutyric acid as a connecting chain.
[0065] Mass spectrometry and nuclear magnetic resonance spectroscopy were used to determine the structure of the prodrug in Example 3. The results are as follows: Figure 3 The results of nuclear magnetic resonance spectrum analysis are as follows: γ-DTX-SS-OA.
[0066] 1 H NMR(600MHz,Chloroform-d)δ8.11(d,J=7.5Hz,2H,Ar-H),7.60(t,J=7.4Hz,1H,Ar-H),7.50(t,J=7.8Hz,2H,Ar-H),7.39(t,J=7.7 Hz,2H,Ar-H),7.35–7.27(m,3H,Ar-H),6.24(s,1H,-OCO-NH-),5.69(d,J=7.1Hz,1H,2'-H),5.52–5.31(m,5H,3'-H,2*-OH,-CH2-C H =C H -CH2-),5.23(s,1H,10- H ),4.96(dd,J=9.6,2.5Hz,1H,13-H),4.32(d,J=8.5Hz,1H,20-C H 2a),4.30–4.24(m,5H,2-H and-OC H2 C H2O-), 4.19(d, J=8.6Hz,1H,20-C H 2b),3.93(d,J=7.1Hz,1H,5-H),2.84(s,1H,-OH),2.69(t,J=7.1Hz,2H,
[0067] -SC H2 -),2.66–2.51(m,4H,-SC H2 CH2C H2 CO-),2.49-2.38(m 6H,7-H,-SCH2CH2C H2 CO-,-OCOC H3 ),2.36-2.27(m,3H,-COC H2 CH2-,14-Ha),2.21–2.13(m,1H,14-Hb),2.05–1.96(m,8H,-C H2 -CH=CH-C H2 -,2*-SCH2C H 2CH2CO-),1.95(s,3H,18-C H3 ),1.92–1.80(m,2H,3-H,6-Ha),1.75(s,3H,19-C H3 ),1.67–1.58(m,3H,6-Hb,-OCOCH2C H2 -),1.35–1.25(m,29H,-C(CH3)3,-(CH2) 10 ),1.23(s,3H,16-C H3 ),1.12(s,3H,17-C H3 ),0.88(t,J=7.0Hz,3H,-CH2C H3 ).
[0068] Mass spectrometry results are MS (ESI) m / z for C 71 H 101 NO 19 S2[M+Na] + =1358.6306.
[0069] Comparative Example: Synthesis of docetaxel-oleic acid prodrug (α-DTX-SS-OA) with 2,2'-dithiodiacetic acid as the linker.
[0070] An appropriate amount of ethylene glycol (0.1 mmol) was placed in a three-necked flask, and p-toluenesulfonic acid (0.3 mmol) was added to the three-necked flask. The flask was heated to 110°C under N2 protection, and 5 mL of oleic acid (1 mmol) solution dissolved in toluene was slowly dripped into the reaction flask for 2-3 hours. The reaction was monitored to be complete by TLC. After the reaction was completed, the stratification was allowed to stand, and toluene was used to extract until the ethylene glycol layer showed no product on TLC. The toluene layers were combined and then washed with saturated NaHCO3 solution until neutral, dried over anhydrous sodium sulfate, filtered, and evaporated to dryness to obtain a reddish-brown oily liquid. The intermediate 1 was separated and purified by column chromatography using a cyclohexane-ethyl acetate elution system to obtain a colorless oily liquid.
[0071] A proper amount of 2,2'-dithiodiacetic acid (2 mmol) was dissolved in 4 mL of acetic anhydride and placed in a 25 mL eggplant-shaped bottle. After complete dissolution, the mixture was magnetically stirred at 25°C for 2 hours and then transferred to a 100 mL eggplant-shaped bottle. Three times the amount of toluene was added. Toluene and acetic anhydride were removed by vacuum distillation. A proper amount of dichloromethane was added to dissolve the dithiodiacetic anhydride formed. Then, the intermediate 1 (1 mmol) dissolved in dichloromethane was added. A solution of 4-dimethylaminopyridine (DMAP, 0.2 mmol) dissolved in dichloromethane was slowly added dropwise. The mixture was magnetically stirred at 25°C for 12 hours. The intermediate product 2 is obtained, and the column chromatography is separated and purified using a cyclohexane-acetone elution system; after obtaining the purified product of the previous step (1mmol), a dichloromethane solution of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 2mmol), 1-hydroxybenzotriazole (HOBt, 1mmol), and 4-dimethylaminopyridine (DMAP, 0.5mmol) is added, activated in an ice bath at 0°C for 2 hours, and then docetaxel (0.8mmol) dissolved in dichloromethane is added, and stirred at 25°C for 36-48 hours. After the reaction is completed, the product is separated using a preparative phase to obtain a docetaxel-oleic acid prodrug (α-DTX-SS-OA) with 2,2'-dithiodiacetic acid as a connecting chain.
[0072] Mass spectrometry and nuclear magnetic resonance spectroscopy were used to determine the structure of the prodrug in Example 1. The results are as follows: Figure 1 The results of nuclear magnetic resonance spectrum analysis are as follows: α-DTX-SS-OA.
[0073] 1H NMR(600MHz,Chloroform-d)δ8.11(d,J=7.5Hz,2H,Ar-H),7.61(t,J=7.4Hz,1H,Ar-H),7.51(t,J=7.8Hz,2H,Ar-H),7.39(t,J=7.7Hz,2H,Ar-H),7.33(d,J=7.4Hz,2H,Ar-H),7.30(t,J=7.4Hz,1H,Ar-H),6.23(s,1H,-OCO-NH-),5.74-5.65(m,2H,2’-H,3’-H),5.48(s,1H,-OH),5.39-5.29(m,3H,-CH2-C H =C H -CH2-,-OH),5.23(s,1H,10- H ),4.96(dd,J=9.7,2.5Hz,1H,13-H),4.39–4.26(m,6H,20-C H 2a,2-H and-OC H2 C H2 O-),4.19(d,J=8.5Hz,1H,20-C H 2b),3.92(d,J=7.1Hz,1H,5-H),3.63–3.49(m,4H,-C H2 SSC H2- ),2.83(s,1H,-OH),2.61–2.54(m,1H,7-H),2.43(s,3H,-OCOC H3 ),2.35-2.27(m,3H,-COC H2 CH2-,14-Ha),2.19-2.11(m,1H,14-Hb),2.04-1.98(m,4H,-C H2 -CH=CH-C H2 -),1.94(s,3H,18-C H3 ),1.90–1.81(m,2H,3-H,6-Ha),1.75(s,3H,19-C H3 ),1.71-1.57(m,3H,6-Hb,-OCOCH2C H2- ),1.43–1.23(m,29H,-C(CH3)3,-(CH2) 10 ),1.22(s,3H,16-C H3 ),1.12(s,3H,17-C H3 ),0.88(t,J=7.0Hz,3H,-CH2C H3 )。
[0074] Mass spectrometry results are MS (ESI) m / z for C 67 H 93 NO 19 S2[M+Na] + =1302.5670.
[0075] Example 3: Preparation of PEG-modified docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles.
[0076] PEGylated docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles: Precisely weigh DSPE-PEG 2k 2 mg of PEG-1-dole-1-ol and 8 mg of docetaxel-fatty acid small molecule prodrug prepared in Examples 1 and 2 and Comparative Example were mixed and dissolved in 1 mL of ethanol. The ethanol solution was slowly added dropwise to 4 mL of deionized water under stirring to spontaneously form uniform nanoparticles. The ethanol was removed by vacuum distillation to obtain an ethanol-free nanoparticle preparation, namely DSPE-PEG. 2k Modified docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles: specifically, α-DTX-SS-OA nanoparticles, β-DTX-SS-OA nanoparticles and γ-DTX-SS-OA nanoparticles (see Figure 4 and Table 1).
[0077] Table 1. Particle size and size distribution of PEG-modified docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles
[0078]
[0079] The results are shown in Table 1. The particle sizes of the nanoparticles all meet the requirements, and the particle size distribution is less than 0.2.
[0080] Further evaluation was performed using the above-mentioned nanoparticles assembled with prodrugs of different configurations:
[0081] 1) FBS stability experiment of PEG-modified docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles.
[0082] The stability of the prodrug self-assembled nanoparticles was investigated by incubating them in PBS solution (containing 10% FBS, pH 7.4). Figure 5As shown in the figure, after incubation in PBS solution (containing 10% FBS, pH 7.4) for 24 hours, the particle size of α-DTX-SS-OA nanoparticles increased to a certain extent. In contrast, the changes in the particle size of β-DTX-SS-OA nanoparticles and γ-DTX-SS-OA nanoparticles were negligible. This suggests that α-DTX-SS-OA nanoparticles may be more sensitive to the surrounding environment and have poor stability, while β-DTX-SS-OA nanoparticles and γ-DTX-SS-OA nanoparticles have better assembly ability and stability.
[0083] 2) Plasma chemical stability test of PEG-modified docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles.
[0084] The in vitro plasma chemical stability of PEG-modified small molecule prodrug self-assembled nanoparticles was investigated. The three prodrug nanoparticles were mixed with blank rat plasma (1:20, v / v) and incubated in a 37°C constant temperature oscillator (100 rpm). 50 μL samples were taken at 0, 2, 4, 6, 8, 12 and 24 h, 150 μL acetonitrile was added, vortexed for 3 min, centrifuged at 13000 rpm for 10 min, and the supernatant was taken to determine the plasma drug concentration.
[0085] The results are as follows Figure 6 As shown in the figure, β-DTX-SS-OA nanoparticles and γ-DTX-SS-OA nanoparticles exhibit good plasma chemical stability. After 24 hours of incubation with plasma, about 90% of the prodrugs were still not degraded. However, the chemical stability of α-DTX-SS-OA nanoparticles was poor. After 24 hours of incubation, the release amount of docetaxel was much greater than that of β-DTX-SS-OA nanoparticles and γ-DTX-SS-OA nanoparticles. This shows that the prodrugs bridged by the β-position and γ-disulfide bonds have good plasma chemical stability, which provides a guarantee for their pharmacokinetic behavior in vivo.
[0086] From the structure-activity relationship analysis of FBS stability and plasma chemical stability test results, there is a certain correlation between the release rate of docetaxel and the length of the carbon chain between the sulfur atom and the ester bond. The sulfur atom in the α-DTX-SS-OA nanoparticles is located at the α position of the ester bond, the carbon chain is the shortest, and the drug release is the fastest. For γ-DTX-SS-OA nanoparticles, although the carbon chain between the disulfide bond and the ester bond is the longest, the sulfhydryl group at the γ position can attack the carbon atom on the carbonyl group, causing the ester bond to break to form a stable five-membered ring structure, thereby promoting the rapid release of docetaxel. Therefore, γ-DTX-SS-OA nanoparticles have a stronger responsive drug release ability than β-DTX-SS-OA nanoparticles, and β-DTX-SS-OA nanoparticles are expected to achieve the advantages of long-acting sustained-release drugs.
[0087] 3) In vivo antitumor experiment of PEG-modified docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles.
[0088] The antitumor activity of PEG-modified small molecule prodrug self-assembled nanoparticles on 4T1 ectopic tumor model was investigated. 6 cells / 100 μL) were inoculated on the right back of female Balb / C mice to construct a 4T1 ectopic tumor model. 3 At the same time, tumor-bearing mice were randomly divided into five groups, each group was given normal saline, taxotere and PEG-modified small molecule prodrug self-assembled nanoparticles prepared in Example 1-3. The drug was administered once every 3 days for 6 consecutive times. The dosage was 30 mg / kg calculated based on docetaxel. After administration, the survival status of the mice was observed every day, the body weight was weighed, and the tumor volume was measured. The tumor-bearing mice were killed one day after the last administration, and the tumors were obtained for further analysis and evaluation.
[0089] The results are as follows Figure 7 As shown in the end-point test of the study, we found that the tumors of mice treated with normal saline grew rapidly, and all mice in the Taxotere group died after only three intravenous injections, which was extremely toxic. It is worth noting that α-DTX-SS-OA nanoparticles can cause lasting tumor shrinkage, and the tumor inhibition effect is even better than DTX; due to its redox-sensitive properties, the drug release is faster, which to a certain extent caused the weight loss of mice, and its safety is worrying. Therefore, this also reminds us that α-DTX-SS-OA nanoparticles may not be suitable for preparation into an efficient and safe drug delivery system. In contrast, β-DTX-SS-OA nanoparticles and γ-DTX-SS-OA nanoparticles have both anti-tumor activity and safety, and do not cause significant nonspecific toxicity to the body, and are good formulas for cancer treatment.
[0090] 4) Pharmacokinetic experiments of PEG-modified docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles.
[0091] SD rats were randomly divided into groups, with 6 rats in each group. Taxotere, α-DTX-SS-OA nanoparticles, β-DTX-SS-OA nanoparticles and γ-DTX-SS-OA nanoparticles were injected into the tail vein, and the equivalent dose of Taxotere was 4 mg / kg. After administration, blood was collected from the rat eye sockets at the preset time points, and plasma was obtained by centrifugation. The plasma samples were quickly stored in a -80°C refrigerator. UPLC-MS-MS was used to determine the blood concentrations of prodrugs (α-DTX-SS-OA, β-DTX-SS-OA, γ-DTX-SS-OA) and the parent drug docetaxel in plasma.
[0092] The results are as follows Figure 8As shown in the figure, after injection, docetaxel in Taxotere is quickly cleared from the blood. In contrast, the prodrug self-assembled nanoparticles significantly prolong the retention time of docetaxel in plasma. The area under the drug-time curve (AUC) of total DTX of α-DTX-SS-OA nanoparticles, β-DTX-SS-OA nanoparticles, and γ-DTX-SS-OA nanoparticles is 71.69, 223, and 143 times higher than that of docetaxel solution, respectively. In contrast, α-DTX-SS-OA nanoparticles have the worst stability and high redox sensitivity. After entering the blood, they quickly disaggregate and release a large amount of docetaxel, which affects their pharmacokinetic behavior. The colloidal stability of γ-DTX-SS-OA nanoparticles is slightly worse, but the AUC is significantly improved compared with the docetaxel solution, and its AUC is twice that of α-DTX-SS-OA nanoparticles. It is worth noting that the β-disulfide bond has the most significant effect on the pharmacokinetic behavior of prodrug self-assembled nanoparticles. The circulation time of β-DTX-SS-OA nanoparticles in the body is significantly prolonged, and the AUC is three times that of α-DTX-SS-OA nanoparticles.
[0093] In summary, chemical linking chains at different positions will affect the anti-tumor effect of prodrugs. By extending the intermediate chemical linking bond, the safety of docetaxel-fatty acid prodrug is significantly improved. The above results once again prove the advantages of docetaxel-fatty acid small molecule prodrug self-assembled nanoparticles.
Claims
1. A docetaxel-fatty acid prodrug compound, characterized in that: The compound is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, Wherein, n=2 or 3; R is oleic acid.
2. The docetaxel-fatty acid prodrug compound according to claim 1, characterized in that: The compound is the following compound or a pharmaceutically acceptable salt thereof, When n=2 in the general formula (I), it is docetaxel-oleic acid prodrug (β-DTX-SS-OA) with 3,3'-dithiodipropionic acid as the connecting chain; When n=3 in the general formula (I), it is docetaxel-oleic acid prodrug (γ-DTX-SS-OA) with 4,4'-dithiodibutyric acid as the connecting chain; 3. A method for synthesizing the docetaxel-fatty acid prodrug compound according to claim 1, characterized in that: Step 1: The fatty acid reacts with ethylene glycol under the catalysis of p-toluenesulfonic acid to obtain fatty acid-ethylene glycol ester; Step 2: The fatty acid-ethylene glycol ester undergoes a ring-opening esterification reaction with a dibasic acid anhydride (3,3'-dithiodipropionic anhydride or 4,4'-dithiodibutyric anhydride) under the catalysis of DMAP to obtain an intermediate product; Step 3: The intermediate product undergoes an esterification reaction with docetaxel under the catalysis of HOBt, EDCI and DMAP, and is separated and purified to obtain the compound represented by the general formula (I).
4. The method for synthesizing the docetaxel-fatty acid prodrug compound according to claim 3, characterized in that: In the step 1, the molar ratio of p-toluenesulfonic acid: fatty acid: ethylene glycol is 1:(1-3):(5-15).
5. The method for synthesizing the docetaxel-fatty acid prodrug compound according to claim 3, characterized in that: In the step 2, the molar ratio of DMAP: fatty acid-ethylene glycol ester: dibasic acid anhydride is 1:(1-10):(5-15).
6. The method for synthesizing the docetaxel-fatty acid prodrug compound according to claim 3, characterized in that: In the step 3, the molar ratio of intermediate product:HOBt:EDCI:DMAP:docetaxel=1:(1-10):(2-6):(0.2-5):(0.5-10).
7. A docetaxel-fatty acid prodrug compound self-assembled nanoparticle, characterized in that: The prodrug compound self-assembled nanoparticles as described in claim 1 are non-PEGylated small molecule prodrug self-assembled nanoparticles, PEG-modified / active targeting group-modified small molecule prodrug self-assembled nanoparticles, or small molecule prodrug self-assembled nanoparticles encapsulating fluorescent substances / hydrophobic drugs.
8. The docetaxel-fatty acid prodrug compound self-assembled nanoparticles according to claim 7, characterized in that: The non-PEGylated small molecule prodrug self-assembled nanoparticles are: (1) dissolving the prodrug compound of claim 1, and adding the dissolved solution dropwise into water under stirring conditions, so that docetaxel-fatty acid prodrug spontaneously forms uniform nanoparticles; (2) removing the organic solvent in the preparation by a reduced pressure rotary evaporation method to obtain non-PEGylated small molecule prodrug self-assembled nanoparticles; The PEG-modified / active targeting group-modified small molecule prodrug self-assembled nanoparticles: (1) mixing and dissolving a modifier and the prodrug compound of claim 1, and slowly dropping the dissolved solution into water under stirring conditions, so that docetaxel-fatty acid small molecule prodrug spontaneously forms uniform nanoparticles, wherein the modifier is a PEG modifier or an active targeting modifier, and the mass ratio is docetaxel-fatty acid small molecule prodrug: modifier=(20-1):1; (2) removing the organic solvent in the preparation by a reduced pressure rotary evaporation method to obtain PEG-modified / active targeting group-modified small molecule prodrug self-assembled nanoparticles; The small molecule prodrug self-assembled nanoparticles encapsulating the hydrophobic fluorescent substance or drug: (1) Mixing and dissolving a PEG modifier, a hydrophobic fluorescent substance or a drug with the prodrug compound of claim 1, slowly dropping the solution into water under stirring conditions, and docetaxel-fatty acid small molecule prodrug spontaneously forms uniform nanoparticles; in terms of mass ratio, the prodrug compound of claim 1: PEG modifier: hydrophobic fluorescent substance or drug = (20-1): 1: (1-5); (2) The organic solvent in the preparation is removed by a reduced pressure rotary evaporation method to obtain small molecule prodrug self-assembled nanoparticles encapsulating a hydrophobic fluorescent substance or a drug.
9. A use of the docetaxel-fatty acid prodrug compound according to claim 1, characterized in that : The use of the compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof, or the docetaxel-fatty acid prodrug compound self-assembled nanoparticles according to claim 7 in the preparation of an anti-tumor drug with both effectiveness and safety.
Citation Information
Patent Citations
Triglyceride prodrug based on lymphatic mediated transport and preparation method thereof
CN109851593A
Disulfide bond bridged docetaxel-fatty acid prodrugs and self-assembled nanoparticles thereof
CN112604002A
